Join

Compare · FIXX vs NVO

FIXX vs NVO

Side-by-side comparison of Homology Medicines Inc. (FIXX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both FIXX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVO is the larger of the two at $183.82B, about 1024.4x FIXX ($179.5M).
  • NVO has hit the wire 5 times in the past 4 weeks while FIXX has been quiet.
  • NVO has more recent analyst coverage (25 ratings vs 10 for FIXX).
MetricFIXXNVO
Company
Homology Medicines Inc.
Novo Nordisk A/S
Price
$0.96+7.48%
$41.18+6.93%
Market cap
$179.5M
$183.82B
1M return
-
+13.32%
1Y return
-
-34.24%
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
2018
News (4w)
0
5
Recent ratings
10
25
FIXX

Homology Medicines Inc.

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase I/II pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II. Homology Medicines, Inc. was incorporated in 2015 and is based in Bedford, Massachusetts.

NVO

Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Latest FIXX

Latest NVO